Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.-Reference-Cited by-同舟云学术

Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.

Published:1990-07-28 Issue:6745 Volume:301 Page:205-210
ISSN:0959-8138
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

van den Meiracker A H,Admiraal P J,Man in 't Veld A J,Derkx F H,Ritsema van Eck H J,Mulder P,van Brummelen P,Schalekamp M A

Publisher

BMJ

Subject

General Earth and Planetary Sciences,General Environmental Science,General Engineering

Reference22 articles.

1. A study of the renin inhibitor H142 in man;Webb, D.J.; Manhem, P.J.O.; Ball, S.G.; etal;J Hypertens,1985

2. Hemodynamic effects of a competitive renin inhibitory peptide in man: evidence for multiple mechanisms of action;Zusman, R.M.; Burton, J.; Christensen, D.; Dodds, A.; Haber, E.;Trans Am Assoc Physicians

3. Pharmacological investigations of a new renin inhibitor in normal sodiumunrestricted volunteers;M, De Gasparo; F, Cumin; J, Nussberger; TT, Guyenne; JM, Wood; J, Menard;BrJ Clin Pharmacol,1989

4. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans;Delabays, A.; Nussberger, J.; Porchet, M.;Hypertension,1989

5. Hemodynamic and biochemical consequences of renin inhibition hy infusion of CGP 38560A in normal volunteers;Nussberger, J.; Delabays, A.; De Gasparo, M.;Hypertension,1989

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aliskiren displays long-lasting interactions with human renin;Naunyn-Schmiedeberg's Archives of Pharmacology;2011-12-23

2. Antihypertensives: Renin Inhibitors;Burger's Medicinal Chemistry and Drug Discovery;2010-09-15

3. Endogenous Vasoactive Peptides;Burger's Medicinal Chemistry and Drug Discovery;2010-09-15

4. Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering?;Cardiology Clinics;2008-11

5. RENIN INHIBITION WITH ALISKIREN;Clinical and Experimental Pharmacology and Physiology;2008-04